Trial redesign for the phase II/III DETECTION trial: circulating tumour DNA-guided therapy for stage IIB/C melanoma after surgical resection

被引：1

作者：

Muinonen-Martin, Andy ^{[1
]}

Lee, Rebecca ^{[2
,3
]}

Rothwell, Dominic ^{[4
]}

Jackson, Richard ^{[5
]}

Smith, Nigel ^{[4
]}

Wong, Stephen ^{[6
,7
]}

Kelso, Noel ^{[4
]}

Hewitt, Chelsee ^{[6
]}

Mitchell, Jackie ^{[4
]}

Jones, Kate ^{[6
]}

Turajlic, Samra ^{[8
]}

Corrie, Pippa ^{[9
]}

Marais, Richard ^{[10
]}

Middleton, Mark ^{[11
]}

Dawson, Sarah-Jane ^{[6
,7
,12
]}

Sandhu, Shahneen ^{[6
,7
]}

Dive, Caroline ^{[4
]}

Lorrigan, Paul ^{[2
]}

机构：

[1] Leeds Teaching Hosp NHS Trust, Leeds, England

[2] Christie NHS Fdn Trust, Manchester, England

[3] Div Canc Sci, Manchester, Lancs, England

[4] Canc Res UK Manchester Inst, Canc Biomarker Ctr, Manchester, Lancs, England

[5] Univ Liverpool, Liverpool Clin Trials Unit, Liverpool, England

[6] Peter MacCallum Canc Ctr, Melbourne, Australia

[7] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Australia

[8] Royal Marsden Hosp, Dept Med Oncol, London, England

[9] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[10] Univ Manchester, Manchester Inst, Mol Oncol Grp, Canc Biomarker Ctr, Manchester, England

[11] Churchill Hosp, Dept Med Oncol, Oxford, England

[12] Univ Melbourne, Ctr Canc Res, Melbourne, Australia

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷

关键词：

D O I：

10.1093/bjd/ljad113.084

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P56

引用

页数：1

共 50 条

[21] Minimal residual disease (MRD) detection using a tumour naive circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Day, D.
Starus, A.
Gebski, V.
Simes, J.
Hayes, T.
Padinharakam, S.
Strickland, A. H.
Briscoe, K.
Varma, S.
Barnet, M.
Jackson, C.
Horvath, L. G.
Price, T. J.
Tebbutt, N.
Karki, B.
Diakos, C. I.
Chia, J.
Toh, H. C.
Jones, F. S.
Segelov, E.
ANNALS OF ONCOLOGY, 2023, 34 : S426 - S427
[22] Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial
Luke, J.
Rutkowski, P.
Queirolo, P.
Del Vecchio, M.
Mackiewicz, J.
Sileni, V. Chiarion
De la CruzMerino, L.
Khattak, M. A.
Schadendorf, D.
Long, G. V.
Ascierto, P. A.
Mandala, M.
De Galitiis, F.
Sondak, V.
Scolyer, R. A.
Kirkwood, J. M.
Chen, K.
Ibrahim, N.
Ahsan, S.
Eggermont, A. M. M.
ANNALS OF ONCOLOGY, 2021, 32 : S1314 - S1315
[23] A Phase II/III Randomized Controlled Trial of Adjuvant Radiotherapy, Concurrent Chemoradiotherapy after Surgery Versus Surgery Alone in Patients with Stage IIB-III Esophageal Squamous Cell Carcinoma
Ni, W.
Xiao, Z.
Zhou, Z.
Wang, X.
Chen, D.
Qinfu, F.
Liang, J.
Lv, J.
Bi, N.
Deng, L.
Zhang, T.
Wang, W.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E193 - E193
[24] Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial
Filippi, A. R.
Garcia-Campelo, M. R.
Paoli, J-B.
Kowalski, D. M.
Bennati, C.
Borghetti, P.
Cortinovis, D. L.
Delmonte, A.
Genova, C.
Mroz, R. M.
Nawrocki, S.
Toledano, I.
Tonini, G.
Stewart, R.
Zhu, Z.
Wetherill, G.
Georgoulia, N. E.
Perez, I. Diaz
Dziadziuszko, R.
ANNALS OF ONCOLOGY, 2024, 35 : 1241 - 1241
[25] A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma
Ni, Wenjie
Yu, Shufei
Zhang, Wencheng
Xiao, Zefen
Zhou, Zongmei
Chen, Dongfu
Feng, Qinfu
Liang, Jun
Lv, Jima
Gao, Shugeng
Mao, Yousheng
Xue, Qi
Sun, Kelin
Liu, Xiangyang
Fang, Dekang
Li, Jian
Wang, Dali
BMC CANCER, 2020, 20 (01)
[26] A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma
Wenjie Ni
Shufei Yu
Wencheng Zhang
Zefen Xiao
Zongmei Zhou
Dongfu Chen
Qinfu Feng
Jun Liang
Jima Lv
Shugeng Gao
Yousheng Mao
Qi Xue
Kelin Sun
Xiangyang Liu
Dekang Fang
Jian Li
Dali Wang
BMC Cancer, 20
[27] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Eggermont, Alexander M. M.
Chiarion-Sileni, Vanna
Grob, Jean-Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo A.
Richards, Jon M.
Lebbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Konto, Cyril
Hoos, Axel
de Pril, Veerle
Gurunath, Ravichandra Karra
de Schaetzen, Gaetan
Suciu, Stefan
Testori, Alessandro
LANCET ONCOLOGY, 2015, 16 (05): : 522 - 530
[28] Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial
Amir Khammari
Jean-Michel Nguyen
Marie-Thérèse Leccia
Bernard Guillot
Soraya Saiagh
Marie-Christine Pandolfino
Anne-Chantal Knol
Gaëlle Quéreux
Anne Chiffolettau
Nathalie Labarrière
Brigitte Dréno
Cancer Immunology, Immunotherapy, 2020, 69 : 1663 - 1672
[29] Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial
Khammari, Amir
Nguyen, Jean-Michel
Leccia, Marie-Therese
Guillot, Bernard
Saiagh, Soraya
Pandolfino, Marie-Christine
Knol, Anne-Chantal
Quereux, Gaelle
Chiffolettau, Anne
Labarriere, Nathalie
Dreno, Brigitte
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (08) : 1663 - 1672
[30] Surgical practice patterns following NCCTG N0338 "Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer."
Apsey, H.
Roy, V.
Pockaj, B.
Northfelt, D.
Sticca, R.
Nikcevich, D. A.
Mattar, B.
Fitch, T.
Perez, E. A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →